Reports indicate that FDA Commissioner Marty Makary attempted to intervene in an ongoing drug review, raising concerns about regulatory independence under new leadership. The incident, described by multiple agency sources, underscores tensions within the agency and potential impacts on the rigor of drug evaluation and approval processes during this critical transition period.